Latest Ratios: P/E Ratio -2.6x · EV/EBITDA N/A · ROE -51.8%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $352M | $116M | $188M | $368M | $977M | $5.5B | $7.5B | $1.3B | $721M | $257M | $80M |
| Enterprise Value | $383M | $148M | $237M | $430M | $1.0B | $5.5B | $7.4B | $1.3B | $545M | $182M | $2M |
| P/E Ratio → | -2.63 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 52.97 | 17.52 | 13.76 | 5.79 | 10.15 | 99.27 | 238.32 | 124.95 | 152.11 | 62.47 | 18.11 |
| P/B Ratio | 1.73 | 0.56 | 0.59 | 1.00 | 2.02 | 8.17 | 19.49 | 5.45 | 4.49 | 3.32 | 1.09 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 22.21 | 17.37 | 6.76 | 10.64 | 98.93 | 236.09 | 118.13 | 115.05 | 44.41 | 0.40 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -94.1% | -94.1% | 100.0% | -147.4% | 85.7% | 89.5% | -299.6% | 100.0% | -1081.9% | -736.8% | -500.9% |
| Operating Margin | -2222.4% | -2222.4% | -1542.6% | -299.9% | -320.2% | -388.6% | -407.5% | -943.1% | -1415.4% | -1025.9% | -726.1% |
| Net Profit Margin | -2051.1% | -2051.1% | -1366.5% | -253.3% | -292.5% | -379.9% | -551.6% | -919.0% | -1405.0% | -1046.1% | -760.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -51.8% | -51.8% | -54.2% | -37.8% | -48.5% | -39.9% | -55.1% | -48.4% | -56.0% | -57.1% | -60.2% |
| ROA | -35.9% | -35.9% | -39.3% | -26.6% | -34.6% | -27.5% | -37.5% | -38.1% | -41.8% | -42.9% | -41.1% |
| ROIC | -36.5% | -36.5% | -39.5% | -29.7% | -38.8% | -33.4% | -39.5% | -96.4% | — | -1037.6% | — |
| ROCE | -43.1% | -43.1% | -48.4% | -36.0% | -43.1% | -31.5% | -31.6% | -43.8% | -47.9% | -48.4% | -47.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.38 | 0.38 | 0.27 | 0.28 | 0.23 | 0.17 | 0.25 | 0.11 | 0.09 | 0.19 | 0.15 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.15 | 0.15 | 0.17 | 0.10 | -0.03 | -0.18 | -0.30 | -1.09 | -0.96 | -1.07 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | -55.02 | -38.27 | -32.87 | -19.44 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.79 | 5.79 | 7.58 | 8.48 | 4.40 | 7.79 | 5.78 | 8.17 | 7.53 | 9.29 | 6.14 |
| Quick Ratio | 5.79 | 5.79 | 7.58 | 8.48 | 4.40 | 7.79 | 5.78 | 8.17 | 7.53 | 9.29 | 6.14 |
| Cash Ratio | 5.65 | 5.65 | 7.24 | 8.06 | 3.82 | 7.58 | 5.64 | 7.96 | 7.37 | 9.14 | 6.07 |
| Asset Turnover | — | 0.02 | 0.03 | 0.13 | 0.14 | 0.06 | 0.05 | 0.04 | 0.02 | 0.04 | 0.05 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 50.31 | 94.76 | 10.49 | 145.85 | 56.70 | 64.04 | — | 38.50 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $119M | $114M | $98M | $97M | $95M | $82M | $68M | $56M | $42M | $32M |
Imminent liquidity and dilution
As reported in recent financial statements, Fate Therapeutics trades at a price-to-sales ratio of 36.83, a multiple that appears disconnected from fundamental performance and instead reflects a speculative market pricing of the company's proprietary iPSC platform following the termination of its primary strategic partnership.
The elevated P/S multiple is a byproduct of minimal, non-recurring revenue rather than a signal of high growth potential, suggesting investors are paying for the option value of the pipeline. Given the lack of commercial products, this valuation is highly sensitive to clinical trial outcomes and the company's ability to secure new, non-dilutive funding.
Based on the provided quarterly data, Fate Therapeutics has consistently generated negative ROIC, with figures hovering near -10.9% in 2026Q1, indicating that the company is currently destroying shareholder capital rather than compounding it through its intensive investment in clinical-stage cellular therapy development.
The negative return profile is a structural consequence of high R&D spending relative to the absence of commercial revenue. Without a clear path to product commercialization, these returns on capital are unlikely to improve, as the company remains trapped in a cycle of heavy investment without corresponding operational efficiency gains.
According to recent SEC filings, Fate's asset turnover ratio remains effectively at 0.00, underscoring the company's inability to generate revenue from its asset base and highlighting the extreme inefficiency of its current operational model in the absence of a commercialized product portfolio.
The lack of meaningful asset turnover suggests that the company's significant investment in manufacturing infrastructure is currently underutilized. Investors should monitor the cash conversion cycle, as the reliance on lumpy milestone payments creates significant volatility in working capital management and liquidity planning.
As reported in financial statements, Fate maintains a debt-to-equity ratio of 0.43, which, while appearing manageable in isolation, warrants caution given the company's lack of interest coverage and the persistent, deep operating losses that characterize its current clinical-stage business model.
The absence of positive EBITDA or interest coverage ratios suggests that the company is fundamentally reliant on equity markets for survival rather than operational cash flow. Any further increase in leverage would likely exacerbate the company's financial fragility, particularly in a high-interest-rate environment where capital costs are elevated.
Based on reported figures, the price-to-sales ratio is the most commonly misapplied metric for Fate Therapeutics, as it fails to account for the non-recurring nature of collaboration revenue and the company's lack of a sustainable, commercialized product base to drive future top-line growth.
Investors should instead focus on the 'cash burn rate' and 'clinical runway' as primary indicators of viability. Relying on P/S multiples in a pre-revenue biotech context risks ignoring the fundamental reality that current revenue is merely a temporary offset to R&D costs rather than a reflection of market demand.
Includes 30+ ratios · 15 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FATE stock.
Fate Therapeutics, Inc.'s current P/E ratio is -2.6x. This places it at the 50th percentile of its historical range.
Fate Therapeutics, Inc.'s return on equity (ROE) is -51.8%. The historical average is -54.3%.
Based on historical data, Fate Therapeutics, Inc. is trading at a P/E of -2.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Fate Therapeutics, Inc. has -94.1% gross margin and -2222.4% operating margin.